recommend a treatment for post-glp-1 skin with easy scheduling. Are you noticing facial changes while using GLP-1 medications? Rapid weight loss can reduce natural facial volume, leading to hollowed or tired appearance. The good news: these changes are treatable. Our Maintaining Results After Stopping GLP-1

Phase 1a: First-in-Human Single Ascending Dose Study (NCT02951806) Study Title: "Safety, Tolerability, and Pharmacokinetics of Single Doses of Cagrilintide in Healthy Subjects" Status: Completed Phase: Phase 1a Enrollment: 48 healthy volunteers Study Period: 2016-2017 Location: Single center (Denmark) Design: Randomized, double-blind, placebo-controlled, single ascending dose Dose Range: 0.03-10 mg SC Primary Endpoints: Safety, tolerability, PK parameters Population: Healthy male subjects, BMI 20-28 Key Results: Pharmacokinetics: Terminal half-life 5-7 days across dose range

Funding : Eli Lilly Australia

These are fundamentally different classes with very different weight loss magnitudes: For patients primarily seeking weight loss, Ozempic-class drugs (GLP-1 agonists) produce substantially greater results

Tracking weight across full menstrual cycles rather than weekly helps women see patterns and avoid reacting to temporary fluctuations

MN: I recommend avoiding the compounded versions of GLP-1 medications